OncoZenge AB (DE:8LY)

FRANKFURT:8LY

8LY

OncoZenge AB

RESEARCH TOOLSreports

Want to see DE:8LY full AI Analyst Report?

OncoZenge AB (8LY) Price & Analysis

0 Followers

8LY Stock Chart & Stats

€0.59

-€0.02(-7.82%)

At close: Jan 08 4:00 PM EST

€0.59

-€0.02(-7.82%)

Day’s Range― - ―

52-Week Range€0.45 - €0.67

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€9.45M

Enterprise Value€106.06M

Total Cash (Recent Filing)€3.71M

Total Debt (Recent Filing)€7.50M

Price to Earnings (P/E)―

Beta0.57

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.20

Shares Outstanding14,048,068

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-139.70

Price to Sales (P/S)30.78

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.09

Revenue Forecast (FY)€923.72K

Bulls Say, Bears Say

Bulls Say

Focused Product PipelineOncoZenge’s business is tightly focused on BupiZenge, a localized buccal formulation for oral mucositis. A single, well-defined asset aimed at a clear unmet clinical need supports a straightforward clinical and commercial strategy and makes partnering or licensing execution easier.

Early Revenue TractionRecording SEK 2.7m revenue in 2025—despite volatility—shows the company can generate revenue or milestone receipts. Durable implication: there is some commercial or developmental monetization capability that can be scaled via partnerships or launches if regulatory steps succeed.

Historic Capital DisciplineBetween 2020–2024 the company operated without debt and with positive equity, indicating prior funding discipline and conservative capital structure. That history suggests management can access and deploy capital prudently or revert to lower leverage via partnerships or equity raises.

Bears Say

Negative Shareholders' Equity & New DebtEquity turning negative and introduction of SEK 7.5m debt materially weaken solvency and financial flexibility. This structural deterioration increases refinancing risk, could constrain partnership negotiations, and raises the probability of dilutive or covenant-driven financing decisions.

Persistent Operating Cash BurnSustained operating cash outflows (~-SEK 13.1m) indicate the company cannot internally fund operations or development. Over the medium term this creates dependency on external capital, increasing dilution risk and potentially forcing trade-offs that slow development or commercialization plans.

Large Ongoing Losses And Weak MarginsDeep operating and net losses with very negative margins show the business is still distant from breakeven. Structurally, this amplifies reliance on successful clinical/regulatory outcomes and external funding; poor earnings durability raises long-term viability risk absent clear funding or commercialization.

8LY FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was €0.45 and its highest was €0.67 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is €9.45M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is in 94 days.

How were OncoZenge AB’s earnings last quarter?

Currently, no data Available

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 14,048,068 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in DE:8LY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).